Veru Inc.’s Promising Phase IIb Results Suggest Investment Opportunity with Enobosarm’s Weight Management Potential
William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...
bovnews1d
Why Is Veru Inc (VERU) Stock Lagging Behind -13.64% from Its 50-Day SMA?
On Monday, Veru Inc (VERU) stock saw a decline, ending the day at $0.64 which represents a decrease of $-0.57 or -47.11% from the prior close of $1.21. The stock opened at $0.64 and touched a low of ...
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...
bovnews6d
Veru Inc (VERU) Stock Rated Buy by B. Riley Securities
Notable insider trades include STEINER MITCHELL SHUSTER, President and CEO at Veru Inc (VERU), who sold 84021 shares on May 15 ’24, at $1.5 each, totaling $0.13 million.
FierceBiotech3d
Veru's drug conserves muscle mass for older patients taking Novo's Wegovy in phase 2 trial
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
Barclays PLC Purchases 139,617 Shares of Veru Inc. (NASDAQ:VERU)
Barclays PLC lifted its position in shares of Veru Inc. (NASDAQ:VERU – Free Report) by 309.2% during the 3rd quarter, ...
BioWorld3d
Veru weight loss study hits primary endpoint, stock drops
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). The side effect of lean mass ...
Oppenheimer maintains Veru stock Outperform rating, $5 target
Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the announcement of encouraging trial results. With the stock currently trading at $0.